AK

Aaron Kantoff

Co-Founder & Managing Partner at Scion Life Sciences

New York, New York

Overview 

Aaron Kantoff is the Co-Founder & Managing Partner at Scion Life Sciences in New York, New York. With a background in venture capital and corporate development, he has served on the boards of multiple biotechnology companies and as a Venture Partner at medicxi, showcasing his expertise in business strategy and financial analysis within the pharmaceutical industry.

Work Experience 

  • Co-Founder & Managing Partner

    2022 - Current

  • Board Member

    2024

    Leading research foundation for the diagnosis and treatment of Pancreatic Cancer

  • Board Member

    2022

    Developing transformative medicines that dramatically improve the lives of patients with immune & inflammatory diseases. Lead program, TOUR001, is an anti-IL6L for treatment of autoantibody mediated diseases and inflammatory cardiovascular disorders. NASDAQ: TRML

Tourmaline Bio is a clinical biotechnology company developing transformative medicines to dramatically improve and prevent immune diseases.

Raised $359,500,000.00 from Cowen Healthcare Investments, Deep Track Capital, Affinity Asset Advisors, Braidwell, StemPoint Capital, Logos Capital, Paradigm BioCapital Advisors, Acuta Capital Partners, TCG Crossover and Qiming Venture Partners USA.

  • Founding Board Member

    2020 - 2024

    Targeted Radiotherapy. Acquired by Bristol Myers Squibb for $4.1B.

RayzeBio is a pharmaceuticals company that develops targeted radiopharmaceutical drugs for cancer.

Raised $418,000,000.00 from Soleus Capital, Ally Bridge Group, Viking Global Investors, Laurion Capital Management, Wellington Management, Sands Capital Ventures and Sofinnova Investments.

  • Board Member

    2020 - 2022

    NASDAQ: CNTA

Centessa Pharmaceuticals is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process.

Raised $875,000,000.00 from Oberland Capital.

  • Venture Partner

    2020 - 2021

  • Board Member

    2018 - 2019

    Leading metabolic disease company. Developing a long-acting Fc Fusion modified fibroblast growth factor 21 (FGF21), AKR-001, for NASH and other metabolic diseases. NASDAQ: AKRO

Akero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.

Raised $951,100,000.00 from Hercules Capital.

  • Board Member

    2016 - 2019

    Developing precision medicines for cardiovascular disease Acquired by Novo Nordisk for $2.1B in total cash considerations

  • Board Member

    2015 - 2019

    Elstar Therapeutics is leveraging recent technological advances in antibody engineering to generate best-in-class multi-specific and multi-functional immunotherapies. These molecules harness our growing understanding of immune modulation to treat a variety of hematological malignancies and solid tumors.

  • Partner

    2011 - 2019

    Apple Tree Partners (ATP), is a venture capital firm that invests in and builds biotech companies.

Apple Tree Partners is a venture capital firm that invests in pharmaceuticals, biotech, medtech, and healthcare services.

Raised $5,000,000.00.

Articles About Aaron

Relevant Websites